Size-Exclusion Chromatography Method for Poly(A) Tail Analysis of mRNA

Applications | 2023 | WatersInstrumentation
GPC/SEC
Industries
Pharma & Biopharma
Manufacturer
Waters

Summary

Significance of the Topic


The polyadenylated tail at the 3’ end of mRNA is a critical feature influencing its stability, translation efficiency and in vivo half-life. Precise measurement of poly(A) tail length is essential for the development, quality control and comparability assessment of mRNA-based therapeutics and vaccines. A streamlined, reproducible analytical method supports accelerated workflow in research and manufacturing of next-generation mRNA modalities.

Objectives and Study Overview


This work describes the development of a rapid, easy-to-implement size-exclusion chromatography (SEC) method to estimate poly(A) tail length after enzymatic release. The method is benchmarked against a complementary ion-pair reversed-phase (IP-RP) LC approach to profile poly(A) heterogeneity. Key goals include minimal sample preparation, robust quantification in the 30–150 nucleotide range and suitability for routine QC environments.

Methodology and Instrumentation


mRNA samples were digested with RNase T1 to cleave at guanosine residues, liberating the poly(A) tail as an oligonucleotide. A quick CIP dephosphorylation step removed 3′ phosphates prior to analysis.
  • Size-Exclusion Chromatography: Waters ACQUITY Premier UPLC system with SM-FTN/QSM, PDA detection at 260 nm, ACQUITY Premier Protein SEC 250 Å, 4.6×150 mm, 1.7 µm column, mobile phase 0.1 M phosphate pH 8.
  • Ion-Pair Reversed-Phase LC: ACQUITY Premier UPLC, PDA at 260 nm, ACQUITY Premier Oligonucleotide BEH C18 300 Å, 2.1×150 mm, 1.7 µm column, 100 mM octylammonium acetate with HFIP in acetonitrile gradients.

Key Results and Discussion


SEC resolved small oligonucleotides (2–30 nt) from the released poly(A) tail. Calibration with synthetic oligo(A) standards (30–150 nt) yielded a linear log(N) versus retention time trend, enabling direct length estimation. Typical poly(A) peaks exhibited fronting and broadening due to a mixture of N-x and N+x species that coelute in SEC. High-resolution IP-RP LC partially separated these variants, revealing a distribution centered on ~124 nt for the EPO mRNA standard. Synthetic 50 and 100 nt standards highlighted impurity profiles and purity challenges in longer oligomers.

Benefits and Practical Applications


This SEC-UV assay offers:
  • Rapid analysis with minimal sample prep.
  • Straightforward calibration and quantification for QC labs.
  • Compatibility with existing UPLC-PDA systems, no MS required.

It provides a complementary view of poly(A) length to IP-RP LC, supporting method orthogonality in mRNA characterization.

Future Trends and Applications


Emerging directions include coupling high-resolution IP-RP LC to mass spectrometry for detailed heterogeneity profiling, automated sample processing for high throughput, and integration with multi-attribute LC-MS workflows. Continued improvements in column surface chemistries and mobile phase design will enhance recovery and resolution of long oligonucleotides up to several hundred nucleotides.

Conclusion


A robust SEC-UV method using a 250 Å pore size column enables fast, reliable estimation of mRNA poly(A) tail length in the 30–150 nt range. Complementary IP-RP LC provides additional insight into tail heterogeneity. Both assays utilize MaxPeak High Performance Surfaces to ensure consistent oligonucleotide recovery, offering practical tools for mRNA therapeutics development and QC.

Reference


  • Packer M. et al. Nat. Commun. 12, 6777 (2021).
  • Jiang T. et al. Anal. Chem. 91, 8500–8506 (2019).
  • Donegan M., Nguyen J.M., Gilar M. J. Chromatogr. A 1666, 462860 (2022).
  • Goyon A., Yehl P., Zhang K. J. Pharm. Biomed. Anal. 182, 113105 (2020).
  • Ivleva V.B. et al. Rapid Commun. Mass Spectrom. 24, 2631–2640 (2010).
  • Gilar M., Neue U.D. J. Chromatogr. A 1169, 139–150 (2007).
  • Gilar M. et al. J. Chromatogr. A 958, 167–182 (2002).
  • Guimaraes G.J. et al. J. Pharm. Biomed. Anal. 208, 114439 (2022).
  • Nguyen J.M. et al. Bioanalysis (2021).
  • Gilar M. et al. J. Chromatogr. A 1650, 462247 (2021).
  • DeLano M. et al. Anal. Chem. 93, 5773–5781 (2021).

Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.

Downloadable PDF for viewing
 

Similar PDF

Toggle
Ion-Pair Reversed-Phase Liquid Chromatography Method for Analysis of mRNA Poly(A) Tail Heterogeneity
Application Note Ion-Pair Reversed-Phase Liquid Chromatography Method for Analysis of mRNA Poly(A) Tail Heterogeneity Martin Gilar, Maissa M. Gaye Waters Corporation Abstract Messenger RNA (mRNA) biopolymers are new therapeutic modalities. Development of effective mRNA vaccines against SARS-CoV-2 virus accelerated the…
Key words
tail, tailmrna, mrnapoly, polyheterogeneity, heterogeneitypair, pairreversed, reversedphase, phaseliquid, liquidion, ionchromatography, chromatographymethod, methodanalysis, analysisssystem, ssystempremier, premierdiisopropylethylamine
Characterizing LNP mRNA
Characterizing LNP mRNA
2024|Waters|Guides
CONSUMABLES GUIDE BOOK Characterizing LNP mRNA LC tools for purity, identity, integrity and concentration determining measurements A Changing Industry mRNA based medicine helped address the COVID-19 pandemic. The viability of using an mRNA construct as a human drug substance has…
Key words
lipid, lipidmrna, mrnarplc, rplcvanguard, vanguardlnp, lnpanion, anionbook, bookaex, aexcolumn, columndiameter, diameterfit, fitconsumables, consumablesguide, guideoligo, oligocsh
Improving Chromatographic Separations Of Biopharmaceuticals With MaxPeak High Performance Surfaces (HPS) Technology
Improving Chromatographic Separations Of Biopharmaceuticals With MaxPeak High Performance Surfaces (HPS) Technology Analytical Solutions Using MaxPeak High Performance Surfaces (HPS) Technology for Biopharmaceutical Therapeutics Biopharmaceutical therapeutics have consistently been the fastest growing segment within the pharmaceutical space and require advances…
Key words
premier, premieracquity, acquityglycan, glycanmaxpeak, maxpeaknucleotide, nucleotideculture, culturehps, hpspeptide, peptideintact, intactsystem, systembioaccord, bioaccordcolumn, columnread, readprotein, proteinglycans
Analysis of mRNA Cap Impurity Profiles and Capping Efficiency Using RapiZyme™ MC1 Ribonuclease
Application Note Analysis of mRNA Cap Impurity Profiles and Capping Efficiency Using RapiZyme™ MC1 Ribonuclease Balasubrahmanyam Addepalli, Tatiana Johnston, Catalin Doneanu, Jamuna Vaishnav, Alexandre Gomes, Christian Reidy, Ying Qing Yu, Matthew A. Lauber Waters Corporation, United States Published on June…
Key words
cap, capmrna, mrnaimpurity, impuritycapping, cappingprofiles, profilesrna, rnaoligonucleotide, oligonucleotidetreat, treatdiseases, diseasessequence, sequencednazyme, dnazymeribozyme, ribozymeprivacy, privacyretained, retainedmapping
Other projects
GCMS
ICPMS
Follow us
FacebookX (Twitter)LinkedInYouTube
More information
WebinarsAbout usContact usTerms of use
LabRulez s.r.o. All rights reserved. Content available under a CC BY-SA 4.0 Attribution-ShareAlike